Extracellular matrix alterations in the skin of patients affected by psoriasis
Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and...
Saved in:
Published in | BMC cell biology Vol. 22; no. 1; pp. 55 - 12 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
29.10.2021
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples.
From each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (n = 23) and the other sample from non-affected skin (n = 23), as well as tissue collected by blepharoplasty from control individuals (n = 18). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and p values < 0.05 were considered significant.
A significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis).
These results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments. |
---|---|
AbstractList | Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples. From each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (n = 23) and the other sample from non-affected skin (n = 23), as well as tissue collected by blepharoplasty from control individuals (n = 18). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and p values < 0.05 were considered significant. A significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis). These results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments. Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples. From each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (n = 23) and the other sample from non-affected skin (n = 23), as well as tissue collected by blepharoplasty from control individuals (n = 18). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and p values < 0.05 were considered significant. A significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis). These results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments. Abstract Background Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples. Methods From each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (n = 23) and the other sample from non-affected skin (n = 23), as well as tissue collected by blepharoplasty from control individuals (n = 18). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and p values < 0.05 were considered significant. Results A significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis). Conclusions These results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments. Background Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples. Methods From each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (n = 23) and the other sample from non-affected skin (n = 23), as well as tissue collected by blepharoplasty from control individuals (n = 18). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and p values < 0.05 were considered significant. Results A significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis). Conclusions These results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments. Background Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples. Methods From each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (n = 23) and the other sample from non-affected skin (n = 23), as well as tissue collected by blepharoplasty from control individuals (n = 18). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and p values < 0.05 were considered significant. Results A significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis). Conclusions These results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments. Keywords: Psoriasis, Heparanase, Heparanase-2, Syndecan-1, Metalloproteinases, TIMP2 Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples.BACKGROUNDPsoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples.From each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (n = 23) and the other sample from non-affected skin (n = 23), as well as tissue collected by blepharoplasty from control individuals (n = 18). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and p values < 0.05 were considered significant.METHODSFrom each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (n = 23) and the other sample from non-affected skin (n = 23), as well as tissue collected by blepharoplasty from control individuals (n = 18). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and p values < 0.05 were considered significant.A significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis).RESULTSA significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis).These results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments.CONCLUSIONSThese results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments. |
ArticleNumber | 55 |
Audience | Academic |
Author | Wagner, Mariana Fatima Muaccad Gama Theodoro, Thérèse Rachell Oyafuso, Luiza Keiko Matsuka Pinhal, Maria Aparecida Silva Filho, Carlos D’. Apparecida Santos Machad |
Author_xml | – sequence: 1 givenname: Mariana Fatima Muaccad Gama surname: Wagner fullname: Wagner, Mariana Fatima Muaccad Gama – sequence: 2 givenname: Thérèse Rachell surname: Theodoro fullname: Theodoro, Thérèse Rachell – sequence: 3 givenname: Carlos D’. Apparecida Santos Machad surname: Filho fullname: Filho, Carlos D’. Apparecida Santos Machad – sequence: 4 givenname: Luiza Keiko Matsuka surname: Oyafuso fullname: Oyafuso, Luiza Keiko Matsuka – sequence: 5 givenname: Maria Aparecida Silva orcidid: 0000-0003-4001-1663 surname: Pinhal fullname: Pinhal, Maria Aparecida Silva |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34715781$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kl9rFDEUxQep2Fr7BXyQAV_qw9TczCSTvAilVF0oCv55DpnMzTZ1drImGdl-ezO7rXaLSCAJN79zSG7O8-Jg9CMWxUsgZwCCv41ABScVoVARUktWwZPiiHIOlRCMHDzYHxYnMd4QktFaSqDPisO6aYG1Ao6KT5ebFLTBYZgGHcqVTsFtSj0kDDo5P8bSjWW6xjL-yBtvy3Uu45hiqa1Fk7Avu9tyHX1wOrr4onhq9RDx5G49Lr6_v_x28bG6-vxhcXF-VRkm21T1rEHboaUS8z2MJACUCiB9R4WUFnUHrO6FyHNTS8rz1FIQopcaABqoj4vFzrf3-katg1vpcKu8dmpb8GGpdEjODKh43fW8E0QS0TRIqDTSckkoJ0AbbE32erfzWk_dCnuTXxf0sGe6fzK6a7X0v5RgjFEpssHpnUHwPyeMSa1cnFuqR_RTVJRJQoRoG5rR14_QGz-FMbdqpiSRDQH5l1rq_AA3Wj__0WyqzrkA3nDGeKbO_kHl0ePKmZwW63J9T_BmT5CZhJu01FOMavH1yz776mFT_nTjPjkZEDvABB9jQKuMS9vI5Fu4QQFRc07VLqcqh09tc6pmKX0kvXf_j-g32KPlmg |
CitedBy_id | crossref_primary_10_1007_s10753_024_02103_5 crossref_primary_10_1016_j_intimp_2023_111046 crossref_primary_10_1186_s13568_023_01517_y crossref_primary_10_1016_j_biopha_2024_116255 crossref_primary_10_1016_j_biochi_2024_03_011 crossref_primary_10_1038_s41598_023_28746_2 crossref_primary_10_3390_biomedicines10051078 crossref_primary_10_1093_bjd_ljae205 crossref_primary_10_3390_ijms26010261 crossref_primary_10_2147_CCID_S421193 crossref_primary_10_3390_ijms231911940 crossref_primary_10_1016_j_jddst_2024_105738 crossref_primary_10_1093_bioinformatics_btae241 crossref_primary_10_4103_ijd_ijd_641_22 |
Cites_doi | 10.1016/j.gene.2014.01.068 10.1074/jbc.270.22.13453 10.1111/dth.12627 10.2340/00015555-1286 10.1074/jbc.M110.116384 10.1186/s12895-018-0079-8 10.1016/S0140-6736(14)61909-7 10.1073/pnas.1611380113 10.1111/febs.13932 10.1080/09546634.2016.1278198 10.1016/j.matbio.2009.01.001 10.1016/S0140-6736(07)61128-3 10.3389/fimmu.2018.00579 10.1186/s12895-020-00099-7 10.1242/jcs.00063 10.1111/j.1749-6632.1999.tb07677.x 10.1007/s00403-012-1251-3 10.1046/j.1523-1747.2000.00138.x 10.1111/febs.12168 10.1159/000083509 10.1002/ijc.20009 10.3390/ijms20225617 10.1016/S0167-4838(99)00279-4 10.1001/archderm.143.12.1559 10.1186/s12875-016-0544-6 10.1001/jama.2020.4006 10.1111/ijd.13604 10.1038/nature05817 10.3390/ijms20061475 10.3390/ijms20184347 10.1007/s10067-016-3460-1 10.1016/j.drup.2016.10.001 10.1007/s40272-015-0137-1 10.1182/blood-2009-07-234757 10.1182/blood-2005-08-3301 10.1080/08820139.2018.1489831 10.1590/abd1806-4841.2019940211 10.3389/fcell.2019.00068 10.1067/mjd.2002.122755 10.4049/jimmunol.1800104 10.1038/jid.2009.391 10.1111/jdv.13854 10.1590/S1807-59322006000500008 10.3389/fonc.2019.00331 10.1016/j.isci.2019.04.034 10.1038/nri1918 10.1096/fj.00-0895fje 10.1038/jid.2012.339 10.2147/TCRM.S113769 10.1007/s00018-013-1496-9 10.1161/01.RES.0000070112.80711.3D |
ContentType | Journal Article |
Copyright | 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
Copyright_xml | – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TM 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12860-021-00395-1 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Nucleic Acids Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Proquest Medical Database ProQuest Biological Science ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2661-8850 1471-2121 |
EndPage | 12 |
ExternalDocumentID | oai_doaj_org_article_63bd6b8090844e029c9f690260124e7c PMC8555298 A681646556 34715781 10_1186_s12860_021_00395_1 |
Genre | Journal Article |
GeographicLocations | Brazil United States--US North America California |
GeographicLocations_xml | – name: Brazil – name: North America – name: United States--US – name: California |
GrantInformation_xml | – fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo grantid: 2016/01357-8). – fundername: ; grantid: 2016/01357-8). |
GroupedDBID | 0R~ 53G 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACUHS ADBBV ADUKV AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE IAO IGS IHR INH ISR ITC LK8 M1P M7P M~E PGMZT PHGZM PHGZT PIMPY PQQKQ PSQYO ROL RPM RSV SOJ SV3 TUS UKHRP ACRMQ C24 CGR CUY CVF ECM EIF NPM OK1 PMFND --- 23N 2WC 3V. 5VS 6J9 7TM 7XB 8FK ACGFO ACGFS ACIHN ACPRK ADRAZ AEAQA AENEX AHBYD AHMBA AHYZX AMKLP AZQEC BAWUL CS3 DIK DU5 DWQXO E3Z F5P GNUQQ GX1 K9. KQ8 O5R O5S OVT P2P PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS PROAC RBZ RNS SBL TR2 U2A WOQ WOW XSB 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c597t-d54efbef29e157c901122810db2899feab153d881534392643972188d9a111413 |
IEDL.DBID | DOA |
ISSN | 2661-8850 |
IngestDate | Wed Aug 27 01:27:43 EDT 2025 Thu Aug 21 14:04:23 EDT 2025 Fri Jul 11 14:53:40 EDT 2025 Mon Jun 30 10:26:24 EDT 2025 Tue Jun 17 21:31:37 EDT 2025 Tue Jun 10 20:37:12 EDT 2025 Fri Jun 27 05:10:29 EDT 2025 Thu Jan 02 22:56:57 EST 2025 Tue Jul 01 03:48:05 EDT 2025 Thu Apr 24 23:06:49 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Heparanase TIMP2 Syndecan-1 Heparanase-2 Psoriasis Metalloproteinases |
Language | English |
License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c597t-d54efbef29e157c901122810db2899feab153d881534392643972188d9a111413 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-4001-1663 |
OpenAccessLink | https://doaj.org/article/63bd6b8090844e029c9f690260124e7c |
PMID | 34715781 |
PQID | 2599094019 |
PQPubID | 44080 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_63bd6b8090844e029c9f690260124e7c pubmedcentral_primary_oai_pubmedcentral_nih_gov_8555298 proquest_miscellaneous_2590088742 proquest_journals_2599094019 gale_infotracmisc_A681646556 gale_infotracacademiconefile_A681646556 gale_incontextgauss_ISR_A681646556 pubmed_primary_34715781 crossref_citationtrail_10_1186_s12860_021_00395_1 crossref_primary_10_1186_s12860_021_00395_1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-10-29 |
PublicationDateYYYYMMDD | 2021-10-29 |
PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-29 day: 29 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC cell biology |
PublicationTitleAlternate | BMC Mol Cell Biol |
PublicationYear | 2021 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | K Brew (395_CR53) 2000; 1477 WB Kim (395_CR18) 2017; 63 E Edovitsky (395_CR28) 2006; 107 CEM Griffiths (395_CR4) 2007; 370 U Lindqvist (395_CR45) 2012; 92 EK Głażewska (395_CR49) 2016; 12 IM Bronckers (395_CR15) 2015; 17 AK Jaiswal (395_CR26) 2018; 201 R Fleischmajer (395_CR48) 2000; 115 L Blavier (395_CR52) 1999; 878 LL Matos (395_CR32) 2006; 61 G Giannelli (395_CR51) 2004; 109 ML Corcoran (395_CR54) 1995; 270 PI Spuls (395_CR17) 2010; 130 K Damevska (395_CR8) 2018; 31 O Bhattacharjee (395_CR24) 2019; 7 R Romini (395_CR11) 2017; 56 JR Bishop (395_CR34) 2007; 446 AH Baker (395_CR50) 2002; 115 AW Armstrong (395_CR1) 2020; 323 RD Sanderson (395_CR36) 2017; 284 M Elkin (395_CR27) 2001; 15 I Vlodavsky (395_CR37) 2016; 29 CR Parish (395_CR33) 2006; 6 I Lerner (395_CR30) 2014; 71 TR Kyriakides (395_CR46) 2009; 28 A Egeberg (395_CR3) 2020; 20 R Visse (395_CR55) 2003; 92 J Schimitt (395_CR23) 2005; 210 CD Mohan (395_CR38) 2019; 15 M Diani (395_CR47) 2019; 20 AG Wade (395_CR20) 2016; 17 A Rendon (395_CR21) 2019; 20 YY Leung (395_CR12) 2017; 36 VC Ramani (395_CR39) 2013; 280 R Parisi (395_CR13) 2013; 133 E Buommino (395_CR44) 2012; 304 WH Boehncke (395_CR19) 2015; 386 A Purushothaman (395_CR41) 2010; 115 395_CR5 F Levy-Adam (395_CR40) 2010; 285 MN Nicholas (395_CR7) 2017; 22 M Abrouk (395_CR22) 2017; 28 M Arnone (395_CR31) 2019; 94 NL Starodubtseva (395_CR42) 2011; 47 IM Michalek (395_CR10) 2017; 31 L Gutter-Kapon (395_CR35) 2016; 113 LM Amezcua-Guerra (395_CR43) 2018; 47 CI Wootton (395_CR6) 2018; 18 A Mezentsev (395_CR25) 2014; 540 AJ Mayfosh (395_CR29) 2019; 29 SC Weiss (395_CR9) 2002; 47 K Kamiya (395_CR14) 2019; 20 C Huerta (395_CR16) 2007; 143 WH Boehncke (395_CR2) 2018; 9 |
References_xml | – volume: 540 start-page: 1 issue: 1 year: 2014 ident: 395_CR25 publication-title: Gene doi: 10.1016/j.gene.2014.01.068 – volume: 270 start-page: 13453 issue: 22 year: 1995 ident: 395_CR54 publication-title: J Biol Chem doi: 10.1074/jbc.270.22.13453 – volume: 31 start-page: e12627 year: 2018 ident: 395_CR8 publication-title: Dermatol Ther doi: 10.1111/dth.12627 – volume: 92 start-page: 372 issue: 4 year: 2012 ident: 395_CR45 publication-title: Acta Derm Venereol doi: 10.2340/00015555-1286 – volume: 285 start-page: 28010 issue: 36 year: 2010 ident: 395_CR40 publication-title: J Biol Chem doi: 10.1074/jbc.M110.116384 – volume: 18 start-page: 11 issue: 1 year: 2018 ident: 395_CR6 publication-title: BMC Dermatol doi: 10.1186/s12895-018-0079-8 – volume: 386 start-page: 983 issue: 9997 year: 2015 ident: 395_CR19 publication-title: Lancet doi: 10.1016/S0140-6736(14)61909-7 – volume: 113 start-page: E7808 issue: 48 year: 2016 ident: 395_CR35 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1611380113 – volume: 284 start-page: 42 issue: 1 year: 2017 ident: 395_CR36 publication-title: FEBS J doi: 10.1111/febs.13932 – volume: 28 start-page: 488 issue: 6 year: 2017 ident: 395_CR22 publication-title: J Dermatolog Treat doi: 10.1080/09546634.2016.1278198 – volume: 28 start-page: 65 issue: 2 year: 2009 ident: 395_CR46 publication-title: Matrix Biol doi: 10.1016/j.matbio.2009.01.001 – volume: 370 start-page: 63 issue: 9583 year: 2007 ident: 395_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(07)61128-3 – volume: 9 start-page: 579 year: 2018 ident: 395_CR2 publication-title: Front Immunol doi: 10.3389/fimmu.2018.00579 – volume: 20 start-page: 3 issue: 1 year: 2020 ident: 395_CR3 publication-title: BMC Dermatol doi: 10.1186/s12895-020-00099-7 – volume: 115 start-page: 3719 issue: 19 year: 2002 ident: 395_CR50 publication-title: J Cell Sci doi: 10.1242/jcs.00063 – volume: 878 start-page: 108 issue: 1 year: 1999 ident: 395_CR52 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.1999.tb07677.x – volume: 304 start-page: 481 issue: 6 year: 2012 ident: 395_CR44 publication-title: Arch Dermatol Res doi: 10.1007/s00403-012-1251-3 – volume: 115 start-page: 771 issue: 5 year: 2000 ident: 395_CR48 publication-title: J Invest Dermatol doi: 10.1046/j.1523-1747.2000.00138.x – volume: 280 start-page: 2294 issue: 10 year: 2013 ident: 395_CR39 publication-title: FEBS J doi: 10.1111/febs.12168 – volume: 22 start-page: 1 issue: 3 year: 2017 ident: 395_CR7 publication-title: Skin Therapy Lett – volume: 210 start-page: 194 issue: 3 year: 2005 ident: 395_CR23 publication-title: Dermatology doi: 10.1159/000083509 – volume: 109 start-page: 782 issue: 5 year: 2004 ident: 395_CR51 publication-title: Int J Cancer doi: 10.1002/ijc.20009 – volume: 20 start-page: 5617 issue: 22 year: 2019 ident: 395_CR47 publication-title: Int J Mol Sci doi: 10.3390/ijms20225617 – volume: 1477 start-page: 267 issue: 1–2 year: 2000 ident: 395_CR53 publication-title: Biochim Biophys Acta doi: 10.1016/S0167-4838(99)00279-4 – volume: 143 start-page: 1559 issue: 12 year: 2007 ident: 395_CR16 publication-title: Arch Dermatol doi: 10.1001/archderm.143.12.1559 – volume: 17 start-page: 145 issue: 1 year: 2016 ident: 395_CR20 publication-title: BMC Fam Pract doi: 10.1186/s12875-016-0544-6 – volume: 323 start-page: 1945 issue: 19 year: 2020 ident: 395_CR1 publication-title: JAMA doi: 10.1001/jama.2020.4006 – volume: 56 start-page: 167 issue: 8 year: 2017 ident: 395_CR11 publication-title: Int J Dermatol doi: 10.1111/ijd.13604 – volume: 446 start-page: 1030 issue: 7139 year: 2007 ident: 395_CR34 publication-title: Nature doi: 10.1038/nature05817 – volume: 20 start-page: 1475 issue: 6 year: 2019 ident: 395_CR21 publication-title: Int J Mol Sci doi: 10.3390/ijms20061475 – volume: 20 start-page: 4347 issue: 18 year: 2019 ident: 395_CR14 publication-title: Int J Mol Sci doi: 10.3390/ijms20184347 – volume: 63 start-page: 278 issue: 4 year: 2017 ident: 395_CR18 publication-title: Can Fam Physician – volume: 47 start-page: 1254 issue: 9 year: 2011 ident: 395_CR42 publication-title: Genetika – volume: 36 start-page: 125 issue: 1 year: 2017 ident: 395_CR12 publication-title: Clin Rheumatol doi: 10.1007/s10067-016-3460-1 – volume: 29 start-page: 54 year: 2016 ident: 395_CR37 publication-title: Drug Resist Updat doi: 10.1016/j.drup.2016.10.001 – volume: 17 start-page: 373 issue: 5 year: 2015 ident: 395_CR15 publication-title: Paediatr Drugs doi: 10.1007/s40272-015-0137-1 – volume: 115 start-page: 2449 issue: 12 year: 2010 ident: 395_CR41 publication-title: Blood doi: 10.1182/blood-2009-07-234757 – volume: 107 start-page: 3609 issue: 9 year: 2006 ident: 395_CR28 publication-title: Blood doi: 10.1182/blood-2005-08-3301 – volume: 47 start-page: 725 issue: 7 year: 2018 ident: 395_CR43 publication-title: Immunol Investig doi: 10.1080/08820139.2018.1489831 – volume: 94 start-page: 76 issue: 2 suppl 1 year: 2019 ident: 395_CR31 publication-title: An Bras Dermatol doi: 10.1590/abd1806-4841.2019940211 – volume: 7 start-page: 68 year: 2019 ident: 395_CR24 publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2019.00068 – volume: 47 start-page: 512 issue: 4 year: 2002 ident: 395_CR9 publication-title: J Am Acad Dermatol doi: 10.1067/mjd.2002.122755 – volume: 201 start-page: 1651 issue: 6 year: 2018 ident: 395_CR26 publication-title: J Immunol doi: 10.4049/jimmunol.1800104 – volume: 130 start-page: 933 issue: 4 year: 2010 ident: 395_CR17 publication-title: J Invest Dermatol doi: 10.1038/jid.2009.391 – volume: 31 start-page: 205 issue: 2 year: 2017 ident: 395_CR10 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.13854 – volume: 61 start-page: 417 issue: 5 year: 2006 ident: 395_CR32 publication-title: Clinics doi: 10.1590/S1807-59322006000500008 – volume: 29 start-page: 331 issue: 9 year: 2019 ident: 395_CR29 publication-title: Front Oncol doi: 10.3389/fonc.2019.00331 – volume: 15 start-page: 360 year: 2019 ident: 395_CR38 publication-title: iScience doi: 10.1016/j.isci.2019.04.034 – volume: 6 start-page: 633 issue: 9 year: 2006 ident: 395_CR33 publication-title: Nat Rev Immunol doi: 10.1038/nri1918 – volume: 15 start-page: 1661 issue: 9 year: 2001 ident: 395_CR27 publication-title: FASEB J doi: 10.1096/fj.00-0895fje – volume: 133 start-page: 377 issue: 2 year: 2013 ident: 395_CR13 publication-title: J Invest Dermatol doi: 10.1038/jid.2012.339 – volume: 12 start-page: 1579 year: 2016 ident: 395_CR49 publication-title: Ther Clin Risk Manag doi: 10.2147/TCRM.S113769 – ident: 395_CR5 – volume: 71 start-page: 2347 issue: 12 year: 2014 ident: 395_CR30 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-013-1496-9 – volume: 92 start-page: 827 issue: 8 year: 2003 ident: 395_CR55 publication-title: Circ Res doi: 10.1161/01.RES.0000070112.80711.3D |
SSID | ssj0002139912 ssj0017810 |
Score | 2.2793849 |
Snippet | Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized... Background Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is... Abstract Background Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors.... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 55 |
SubjectTerms | Age Antibodies Biopsy Disease Enzymes Extracellular matrix Extracellular Matrix - genetics Gelatinase A Gelatinase B Gene expression Heparan sulfate Heparanase Heparanase-2 Humans Immunohistochemistry Inflammation Inflammatory diseases Metalloproteinases Morbidity Patients Polymerase chain reaction Protein expression Proteins Psoriasis Psoriasis - genetics Quality of life Skin diseases Skin lesions Software Statistical analysis Syndecan Syndecan-1 TIMP2 Tissue inhibitor of metalloproteinase 2 |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3faxQxEA5aEXwp_na1ShTBB1m6yW6yyZNUaamCfVAL9xay2aQe2t2zewftf-9MNrd2EfpyHJcJ3E4mM99kZ74Q8raxUui2hrQE4G9eBaZyC8A51xCdglctuAdscP56Io9Pqy8LsUgHbkMqq9z6xOio297hGfk-wHSNXG9Mf1j9yfHWKHy7mq7QuE3uIHUZWnW9mBIuVitWbBtllNwfwBfLIseiBGxJFTmbBaPI2f-_Z74WmuZlk9fi0NF9spsAJD0YV_wBueW7h-TueKXk1SNycngJs_A4HutL6Tky8F_S-E58PJujy44C6KPDL_jSB5qIVQdqY2WHb2lzRVcDPLodlsNjcnp0-OPTcZ7uTMgdpAbrvBWVD40PXHsmaoeNpZyDGtoGM6vgbQMurlUKPgGK8IhHIMqrVlvwehDRnpCdru_8M0KVcpVkNpQOUqoAMCo0vKxs6QVzStg6I2yrPOMSoTjea_HbxMRCSTMq3IDCTVS4YRl5P81ZjXQaN0p_xDWZJJEKO_7QX5yZtLOMLJtWNqrQhaoqX3DtdICUH6nSeOVrl5E3uKIGyS46rKY5s5thMJ-_fzMHUiG9mhAyI--SUOhxlWxqTgBNID_WTHJvJgm70c2Ht4ZjkjcYzD_bzcjraRhnYoVb5_tNlCnQ41c8I09HO5ueuwQEAZ4V9FHPLHCmmPlIt_wZucKVEIJr9fzmv_WC3OO4LSAmc71HdtYXG_8SwNa6eRV31F-RGySc priority: 102 providerName: ProQuest |
Title | Extracellular matrix alterations in the skin of patients affected by psoriasis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34715781 https://www.proquest.com/docview/2599094019 https://www.proquest.com/docview/2590088742 https://pubmed.ncbi.nlm.nih.gov/PMC8555298 https://doaj.org/article/63bd6b8090844e029c9f690260124e7c |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fi9QwEA56Ivhy-NvquUQRfJByTdqkyeOt7HEKLrJ6sPgSkjY5F732sLtw9987k3aXLYK--FKWzQS2k8k3M9mZL4S8cVYKXZeQlkD4mxaBqdRC4Jxq8E7BqxrgARucP83l2XnxcSmWe1d9YU1YTw_cK-5Y5q6WTmU6U0XhM64rHSCjQyYsXviyQvQFn7eXTCEGcwhsNOPbLhkljzsAYpmlWJGA_agiZSNPFAn7_4TlPb80rpncc0Kn98nhED3Sk_5XPyC3fPOQ3O3vk7x5ROaza5iFZ_FYXEovkX7_msY_xPuDObpqKER8tPsBH9pAB1bVjtpY1uFr6m7oVdeCVXar7jE5P519fX-WDhcmpBXkBeu0FoUPzgeuPRNlhV2lnCuW1Q7TquCtA3yrlYInxCE8BiPg4lWtLUAeuLMn5KBpG_-MUKWqQjIb8gryqQAxVHA8L2zuBauUsGVC2FZ5phrYxPFSi58mZhVKml7hBhRuosINS8i73Zyrnkvjr9JTXJOdJPJgxy_AOsxgHeZf1pGQ17iiBpkuGiylubCbrjMfvizMiVTIrSaETMjbQSi0uEp26EwATSA51kjyaCQJW7EaD28NxwxQ0BnILzWSFDKdkFe7YZyJ5W2NbzdRJkO4L3hCnvZ2tnvvHMIHgFXQRzmywJFixiPN6nskCldCCK7V8_-hyRfkHsfNA26b6yNysP618S8hHlu7CbldLssJuTOdzT8vJnEjwnMx_TaJh2e_AWRGMOs |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYIL4k2ggEEgDihq4sSOfUCoQKtd2u4BWmlvxknssgKSpdkV3T_Fb2TGSZZGSL31Eq3icZQde17OzDeEvMyN4KrMICwB9zdMXSxDA45zqMA6OStLUA9Y4Hw4EaPj9NOUTzfIn74WBtMqe53oFXVZF3hGvg1uukKst1i9m_8KsWsUfl3tW2i022Lfrn5DyNa8HX-E9X3F2N7u0YdR2HUVCAtwnhdhyVPrcuuYsjHPCiy9ZEzGUZlj7OGsyUEJlFLCFYw18xYb7KAslQG9ADofnnuFXAXDG2Gwl03XAV6cwWP6whwpthvQ_SIKMQkCS2B5GA-Mn-8R8L8lOGcKh2ma5-ze3i1ys3NY6U67w26TDVvdIdfaFparu2Syewaz8Pgf81npT0T8P6P-G3x7FkhnFQUnkzbf4UftaAfk2lDjM0lsSfMVnTfAatPMmnvk-FK4eZ9sVnVlHxIqZZGK2LikgBDOgdvmcpakJrE8LiQ3WUDinnm66ADMsY_GD-0DGSl0y3ANDNee4ToOyJv1nHkL33Eh9XtckzUlQm_7G_Xpie4kWYskL0UuIxXJNLURU4VyQnloNpbarAjIC1xRjeAaFWbvnJhl0-jxl896R0iEc-NcBOR1R-RqXCXTFUMAJxCPa0C5NaAE6S-Gw_3G0Z32afQ_WQnI8_UwzsSMusrWS08ToYVJWUAetPts_b8T8FhAkwM_ssEOHDBmOFLNvnlscsk5Z0o-uvi1npHro6PDA30wnuw_JjcYigj4A0xtkc3F6dI-AUdvkT_10kXJ18sW578dal65 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Extracellular+matrix+alterations+in+the+skin+of+patients+affected+by+psoriasis&rft.jtitle=BMC+molecular+and+cell+biology&rft.au=Mariana+Fatima+Muaccad+Gama+Wagner&rft.au=Th%C3%A9r%C3%A8se+Rachell+Theodoro&rft.au=Carlos+D%E2%80%99.+Apparecida+Santos+Machado+Filho&rft.au=Luiza+Keiko+Matsuka+Oyafuso&rft.date=2021-10-29&rft.pub=BMC&rft.eissn=2661-8850&rft.volume=22&rft.issue=1&rft.spage=1&rft.epage=12&rft_id=info:doi/10.1186%2Fs12860-021-00395-1&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_63bd6b8090844e029c9f690260124e7c |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2661-8850&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2661-8850&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2661-8850&client=summon |